Related Experiment Videos
99Tcm-solcocitran in the detection of bone malignancy
Acta Radiologica: Therapy, Physics, Biology
|December 1, 1975
Summary
99Tcm-Solcocitran shows limited sensitivity for detecting bone cancer compared to existing methods. This new radiopharmaceutical did not offer advantages over 99Tcm-Diphosphonate or radiography for bone malignancy detection.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- A novel technetium-99m (99Tcm)-labelled compound, 99Tcm-Solcocitran, has been developed.
- This agent is purported to be specific for neoplastic tissue, aiding in the detection of bone and brain malignancies.
Purpose of the Study:
- To evaluate the efficacy of 99Tcm-Solcocitran in detecting bone malignancy.
- To compare its sensitivity against established imaging agents and methods.
Main Methods:
- Comparative study involving 99Tcm-Solcocitran, 99Tcm-Diphosphonate, and conventional radiography.
- Assessment of sensitivity in identifying metastatic bone lesions in patients.
- Evaluation of tracer accumulation in canine fractures.
Main Results:
- 99Tcm-Solcocitran demonstrated lower sensitivity for detecting metastatic bone lesions than 99Tcm-Diphosphonate and radiography.
- Both 99Tcm compounds exhibited accumulation in fractures in canine subjects.
- No significant advantage of 99Tcm-Solcocitran over existing techniques was observed.
Conclusions:
- 99Tcm-Solcocitran does not appear to offer superior performance for bone malignancy detection.
- Current diagnostic modalities remain more sensitive for identifying bone metastases.